203/212Pb标记低分子量化合物用于前列腺癌靶向放射药物治疗的临床前评价
该临床前研究合成了五种基于赖氨酸-尿素-谷氨酸骨架的PSMA靶向低分子量配体(L1-L5),用203Pb进行生物分布和SPECT/CT显像,并评估相应212Pb标记物的 absorbed dose 和抗肿瘤疗效。结果显示203Pb-L1至L5具有快速全身清除和PSMA阳性肿瘤可视化,212Pb-L2在PSMA阳性皮下瘤模型中呈剂量依赖性抑制肿瘤生长,并在微转移模型中较177Lu-PSMA-617显示生存获益,长期毒性研究提示肾脏为剂量限制器官。
要点
- 203Pb-L1至L5标记率高、全身清除快,注射后0.5小时即可SPECT/CT显像PSMA阳性肿瘤。
- 212Pb-L2单次给药在PSMA阳性皮下瘤模型呈剂量依赖性抑制肿瘤生长。
- 212Pb-L2在微转移模型中较177Lu-PSMA-617显示生存获益,肾脏为剂量限制器官。
核心结论
- 203Pb-L1至L5具备适合212Pb-based TRT的药代动力学特征,212Pb-L2的抗肿瘤疗效支持203Pb/212Pb诊疗对用于晚期前列腺癌的PSMA靶向α粒子TRT。
研究设计与样本
- 临床前研究:合成五种基于赖氨酸-尿素-谷氨酸骨架的低分子量配体L1-L5并测定PSMA抑制常数。
- 在荷PSMA(+) PC3 PIP和PSMA(-) PC3 flu侧腹异种移植瘤小鼠中进行203Pb-L1至L5的组织生物分布和SPECT/CT显像。
- 利用生物分布数据确定相应212Pb标记类似物的吸收辐射剂量。
- 在PSMA(+) PC3 PIP、PSMA(-) PC3 flu肿瘤模型及PSMA(+)荧光素酶表达微转移模型中评估212Pb-L2抗肿瘤疗效,并在健康免疫健全CD-1小鼠中进行剂量递增长期毒性评价。
主要发现
- 所有新配体均以高收率和高纯度获得,PSMA抑制活性范围为0.10至17 nM。
- 203Pb-L1至L5以高放射化学产率和高比活度合成,全身清除快。
- 肿瘤和肾脏吸收剂量系数(mGy/kBq)以203Pb-L5最高(31.0,15.2),以203Pb-L2最低(8.0,4.2)。
- 肿瘤/肾脏吸收剂量比以203Pb-L3(3.2)和203Pb-L4(3.6)高于其他药物,但肿瘤/血比更低。
- 注射后0.5小时即可通过SPECT/CT观察到PSMA(+)肿瘤病灶。
关键数值与推荐
- PSMA抑制活性范围为0.10至17 nM。
- 肿瘤和肾脏吸收剂量系数(mGy/kBq):203Pb-L5为31.0和15.2,203Pb-L2为8.0和4.2。
- 肿瘤/肾脏吸收剂量比:203Pb-L3为3.2,203Pb-L4为3.6。
- SPECT/CT可在注射后0.5小时显像PSMA(+)肿瘤病灶。
临床怎么用
- 203Pb/212Pb诊疗对可作为PSMA靶向α粒子TRT的候选方案用于晚期前列腺癌。
- 203Pb可用于对应212Pb标记物的显像替代,支持剂量评估与疗效预测。
- 肾脏为剂量限制器官,临床转化时需关注肾脏辐射剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted radiopharmaceutical therapy (TRT) using α-particle radiation is a promising approach for treating both large and micrometastatic lesions. We developed prostate-specific membrane antigen (PSMA)-targeted low-molecular-weight agents for 212Pb-based TRT of patients with prostate cancer (PC) by evaluating the matching γ-emitting surrogate, 203Pb. Methods: Five rationally designed low-molecular-weight ligands (L1-L5) were synthesized using the lysine-urea-glutamate scaffold, and PSMA inhibition constants were determined. Tissue biodistribution and SPECT/CT imaging of 203Pb-L1-203Pb-L5 were performed on mice bearing PSMA(+) PC3 PIP and PSMA(-) PC3 flu flank xenografts. The absorbed radiation dose of the corresponding 212Pb-labeled analogs was determined using the biodistribution data. Antitumor efficacy of 212Pb-L2 was evaluated in PSMA(+) PC3 PIP and PSMA(-) PC3 flu tumor models and in the PSMA(+) luciferase-expressing micrometastatic model. 212Pb-L2 was also evaluated for dose-escalated, long-term toxicity. Results: All new ligands were obtained in high yield and purity. PSMA inhibitory activities ranged from 0.10 to 17 nM. 203Pb-L1-203Pb-L5 were synthesized in high radiochemical yield and specific activity. Whole-body clearance of 203Pb-L1-203Pb-L5 was fast. The absorbed dose coefficients (mGy/kBq) of the tumor and kidneys were highest for 203Pb-L5 (31.0, 15.2) and lowest for 203Pb-L2 (8.0, 4.2). The tumor-to-kidney absorbed dose ratio was higher for 203Pb-L3 (3.2) and 203Pb-L4 (3.6) than for the other agents, but with lower tumor-to-blood ratios. PSMA(+) tumor lesions were visualized through SPECT/CT as early as 0.5 h after injection. A proof-of-concept therapy study with a single administration of 212Pb-L2 demonstrated dose-dependent inhibition of tumor growth in the PSMA(+) flank tumor model. 212Pb-L2 also demonstrated an increased survival benefit in the micrometastatic model compared with 177Lu-PSMA-617. Long-term toxicity studies in healthy, immunocompetent CD-1 mice revealed kidney as the dose-limiting organ. Conclusion:203Pb-L1-203Pb-L5 demonstrated favorable pharmacokinetics for 212Pb-based TRT. The antitumor efficacy of 212Pb-L2 supports the corresponding 203Pb/212Pb theranostic pair for PSMA-based α-particle TRT in advanced PC.
引用
- Banerjee SR, Minn I, Kumar V, et al. Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer. J Nucl Med. 2019. PMID: 31253744. doi:10.2967/jnumed.119.229393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。